DPDPE-UK14,304 synergy is retained in mu opioid receptor knockout mice

Pain

Volumn 104, Issue 1-2, 2003, Pages 209-217

  Guo, Xiao Hong ^a   Fairbanks, Carolyn A ^a   Stone, Laura S ^a   Loh, Horace H ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Deltorphin II; Synergism; UK14,304; D Pen2,D Pen5 enkehphalin; opioid receptor knockout mice

Indexed keywords

BRIMONIDINE; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; DELTORPHIN; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLORNITHYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; NALTRINDOLE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPINE; WILD TYPE;

EID: 0038499725     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(03)00007-1     Document Type: Article

References (53)

1. Arvidsson U., Dado R.J., Riedl M., Lee J.-H., Law P.Y., Loh H.H., Elde R., Wessendorf M.W. Delta-opioid receptor immunoreactivity: distribution in brain stem and spinal cord and relationship to biogenic amines and enkephalin. J Neurosci. 15:1995;1215-1235.
2. Arvidsson U., Riedl M., Chakrabarti S., Lee J.-H., Nakano A., Dado R.J., Loh H.H., Law P.Y., Wessendorf M.W., Elde R. Distribution and targeting of a μ-opioid receptor (MOR1) in brain and spinal cord. J Neurosci. 15:1995;3328-3341.
3. Cheng P.Y., Liu-Chen L.Y., Pickel V.M. Dual ultrastructural immunocytochemical labeling of mu and delta opioid receptors in the superficial layers of the rat cervical spinal cord. Brain Res. 778:1997;367-380.
4. Collin E., Mauborgne A., Bourgoin S., Benoliel J.J., Hamon M., Cesselin F. Morphine reduces the release of met-enkephalin-like material from the rat spinal cord in vivo by acting at delta opioid receptors. Neuropeptides. 27:1994;75-83.
5. Dado R.J., Law P.Y., Loh H.H., Elde R. Immunofluorescent identification of a delta-opioid receptor on primary afferent nerve terminals. NeuroReport. 5:1993;341-344.
6. DeLander G.E., Wahl J.J. Morphine (intracerebroventricular) activates spinal systems to inhibit behavior induced by putative pain neurotransmitters. J Pharmacol Exp Ther. 251:1989;1090-1095.
7. Fairbanks C.A., Stone L.S., Kitto K.F., Nguyen H.O., Posthumus I.J., Wilcox G.L. Alpha(2C)-adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy. J Pharmacol Exp Ther. 300:2002;282-290.
8. 2 adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice. J Pharmacol Exp Ther. 290:1999;403-412.
9. Gomes I., Jordan B.A., Gupta A., Trapaidze N., Nagy V., Devi L.A. Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J Neurosci. 20:RC110:2000;1-5.
10. He L., Lee N.M. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord. J Pharmacol Exp Ther. 285:1998;1181-1186.
11. Heyman J.S., Mulvaney S.A., Mosberg H.I., Porreca F. Opioid delta-receptor involvement in supraspinal and spinal antinociception in mice. Brain Res. 420:1987;100-108.
12. Horan P., Tallarida R.J., Haaseth R.C., Matsunaga T.O., Hruby V.J., Porreca F. Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: supra- and sub-additivity. Life Sci. 50:1992;1535-1541.
13. Hosohata Y., Vanderah T.W., Burkey T.H., Ossipov M.H., Kovelowski C.J., Sora I., Uhl G.R., Zhang X., Rice K.C., Roeske W.R., Hruby V.J., Yamamura H.I., Lai J., Porreca F. Delta-opioid receptor agonists produce antinociception and [35S]GTPgS binding in mu receptor knockout mice. Eur J Pharmacol. 388:2000;241-248.
14. Hylden J.L.K., Wilcox G.L. Intrathecal morphine in mice: a new technique. Eur J Pharmacol. 67:1980;313-316.
15. Hylden J.L.K., Wilcox G.L. Pharmacological characterization of substance P-induced nociception in mice: modulation by opioid and noradrenergic agonists at the spinal level. J Pharmacol Exp Ther. 226:1983;398-404.
16. Hylden JLK, Wilcox GL. Intrathecal opioids block a spinal action of substance P in mice: functional importance of both μ and δ receptors. Eur J Pharmacol 1986;1:95-8.
17. Inoue M., Shimohira I., Yoshida A., Zimmer A., Takeshima H., Sakurada T., Ueda H. Dose-related opposite modulation by nociceptin/orphanin FQ of substance P nociception in the nociceptors and spinal cord. J Pharmacol Exp Ther. 291:1999;308-313.
18. Jiang Q., Mosberg H.I., Porreca F. Modulation of the potency and efficacy of mu-mediated antinociception by delta agonists in the mouse. J Pharmacol Exp Ther. 254:1990;683-689.
19. Jordan B.A., Devi L.A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature. 399:1999;697-700.
20. Kieffer B.L. Opioids: first lessons from knockout mice. Trends Pharmacol Sci. 20:1999;19-26.
21. Loh H.H., Liu H.C., Cavalli A., Yang W., Chen Y.F., Wei L.N. mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Brain Res Mol Brain Res. 54:1998;321-326.
22. Malmberg A.B., Yaksh T.L. Isobolographic and dose-response analyses of the interaction between intrathecal mu and delta agonists: effects of naltrindole and its benzofuran analog (NTB). J Pharmacol Exp Ther. 263:1992;264-275.
23. Matthes H.W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dolle P., Tzavara E., Hanoune J., Roques B.P., Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene [see comments]. Nature. 383:1996;819-823.
24. Matthes H.W., Smadja C., Valverde O., Vonesch J.L., Foutz A.S., Boudinot E., Denavit-Saubie M., Severini C., Negri L., Roques B.P., Maldonado R., Kieffer B.L. Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor. J Neurosci. 18:1998;7285-7295.
25. 2 in rats exposed to morphine. Proc Natl Acad Sci USA. 89:1992;3696-3700.
26. Miyamoto Y., Portoghese P.S., Takemori A.E. Involvement of delta 2 opioid receptors in the development of morphine dependence in mice. J Pharmacol Exp Ther. 264:1993;1141-1145.
27. Mogil J.S., Grisel J.E. Transgenic studies of pain. Pain. 77:1998;107-128.
28. Mogil J.S., Wilson S.G., Bon K., Lee S.E., Chung K., Raber P., Pieper J.O., Hain H.S., Belknap J.K., Hubert L., Elmer G.I., Chung J.M., Devor M. Heritability of nociception I: responses of 11 inbred mouse strains on 12 measures of nociception. Pain. 80:1999;67-82.
29. Mosberg H.I., Hurst R., Hruby V.J., Gee K., Akiyama K., Yamamura H.I., Galligan J.J., Burks T.F. Cyclic penicillamine containing enkephalin analogs display profound delta receptor selectivities. Life Sci. 33:1983;447-450.
30. Ossipov M., Harris S., Lloyd P., Messineo E. An isobolographic analysis of the antinociceptive effect of systemically and intrathecally administered combinations of clonidine and opiates. J Pharmacol Exp Ther. 255:1990;1107-1116.
31. Ossipov M., Harris S., Lloyd P., Messineo E., Lin B., Bagley J. Antinociceptive interaction between opioids and medetomidine: systemic additivity and spinal synergy. Anesthesiology. 73:1990;1227-1235.
32. Ossipov M., Lozito R., Messineo E., Green J., Harris S., Lloyd P. Spinal antinociceptive synergy between clonidine and morphine, U69593, and DPDPE: isobolographic analysis. Life Sci. 47:1990;PL71-PL76.
33. Ossipov M.H., Kovelowski C.J., Porreca F. The increase in morphine antinociceptive potency produced by carrageenan-induced hindpaw inflammation is blocked by naltrindole, a selective delta-opioid antagonist. Neurosci Lett. 184:1995;173-176.
34. Portoghese P.S., Sultana M., Takemori A.E. Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. Eur J Pharmacol. 146:1988;185-186.
35. Qiu C.Y., Sora I., Ren K., Uhl G., Dubner R. Enhanced delta-opioid receptor-mediated antinociception in mu-opioid receptor-deficient mice. Eur J Pharmacol. 387:2000;163-169.
36. Quock R.M., Burkey T.H., Varga E., Hosohata Y., Hosohata K., Cowell S.M., Slate C.A., Ehlert F.J., Roeske W.R., Yamamura H.I. The delta-opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy. Pharmacol Rev. 51:1999;503-532.
37. Rapaka R.S., Porreca F. Development of delta opioid peptides as nonaddicting analgesics. Pharm Res. 8:1991;1-8.
38. 2 receptors. J Pharmacol Exp Ther. 262:1992;365-374.
39. Schoffelmeer A.N., Yao Y.H., Gioannini T.L., Hiller J.M., Ofri D., Roques B.P., Simon E.J. Cross-linking of human [125I]beta-endorphin to opioid receptors in rat striatal membranes: biochemical evidence for the existence of a mu/delta opioid receptor complex. J Pharmacol Exp Ther. 253:1990;419-426.
40. Sofuoglu M., Portoghese P.S., Takemori A.E. Cross-tolerance studies in the spinal cord of β-FNA-treated mice provides further evidence for delta opioid receptor subtypes. Life Sci. 49:1991;PL1153-PL1156.
41. Sora I., Funada M., Uhl G.R. The mu-opioid receptor is necessary for [D-Pen(2),D-Pen(5)]enkephalin-induced analgesia. Eur J Pharmacol. 324:1997;R1-R2.
42. Sora I., Takahashi N., Funada M., Ujike H., Revay R.S., Donovan D.M., Miner L.L., Uhl G.R. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA. 94:1997;1544-1549.
43. Stimmel B. Adequate analgesia in narcotic dependency. Advances in pain research and therapy. Hill C.S., Fields W.S. Drug treatment of pain in a drug-oriented society. vol. 11:1989;131-138 Raven Press, New York, NY.
44. 2 agonists and is necessary for spinal adrenergic/opioid synergy. J Neurosci. 17:1997;7157-7165.
45. Tallarida R.J. Statistical analysis of drug combinations for synergism [Review]. Pain. 49:1992;93-97. [published erratum appears in Pain 1993;53(3):365].
46. Tallarida R.J. Drug synergism: its detection and applications. J Pharmacol Exp Ther. 298:2001;865-872.
47. Tallarida R.J. The interaction index: a measure of drug synergism. Pain. 98:2002;163-168.
48. Tallarida R.J., Murray R.B. Manual of pharmacological calculations with computer programs. 1987;Springer, NewYork, NY. p. 26-31.
49. Traynor J.R., Elliott J. Delta-opioid receptor subtypes and cross-talk with mu-receptors. Trends Pharmacol Sci. 14:1993;84-86.
50. Tseng L.F., Collins K.A. The tail-flick inhibition induced by beta-endorphin administered intrathecally is mediated by activation of kappa- and mu-opioid receptors in the mouse. Eur J Pharmacol. 214:1992;59-65.
51. Tseng L.F., Narita M., Suganuma C., Mizoguchi H., Ohsawa M., Nagase H., Kampine J.P. Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mouse. J Pharmacol Exp Ther. 292:2000;576-583.
52. Wang H., Wessendorf M.W. Equal proportions of small and large DRG neurons express opioid receptor mRNAs. J Comp Neurol. 429:2001;590-600.
53. Xu J.Y., Fujimoto J.M., Tseng L.F. Involvement of supraspinal epsilon and mu opioid receptors in inhibition of the tail-flick response induced by etorphine in the mouse. J Pharmacol Exp Ther. 263:1992;246-252.